Dawn Everington

2.6k total citations
38 papers, 1.9k citations indexed

About

Dawn Everington is a scholar working on Molecular Biology, Sociology and Political Science and Cancer Research. According to data from OpenAlex, Dawn Everington has authored 38 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Sociology and Political Science and 8 papers in Cancer Research. Recurrent topics in Dawn Everington's work include Prion Diseases and Protein Misfolding (10 papers), Breast Cancer Treatment Studies (8 papers) and Youth Education and Societal Dynamics (6 papers). Dawn Everington is often cited by papers focused on Prion Diseases and Protein Misfolding (10 papers), Breast Cancer Treatment Studies (8 papers) and Youth Education and Societal Dynamics (6 papers). Dawn Everington collaborates with scholars based in United Kingdom, United States and China. Dawn Everington's co-authors include A P M Forrest, Helen Stewart, C. Martín, David T. Baird, R.J. Prescott, Helen Ward, Adrian Harnett, David C. Smith, Colin S. McArdle and W D George and has published in prestigious journals such as The Lancet, The Journal of Clinical Endocrinology & Metabolism and Neurology.

In The Last Decade

Dawn Everington

36 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dawn Everington United Kingdom 20 519 505 348 330 305 38 1.9k
Judy Kirk Australia 30 554 1.1× 579 1.1× 104 0.3× 641 1.9× 614 2.0× 107 3.1k
Marie Wood United States 25 498 1.0× 413 0.8× 110 0.3× 240 0.7× 467 1.5× 79 2.3k
Audrey Ardern‐Jones United Kingdom 24 303 0.6× 688 1.4× 130 0.4× 232 0.7× 224 0.7× 48 2.1k
Wendy Kohlmann United States 28 685 1.3× 588 1.2× 129 0.4× 271 0.8× 878 2.9× 111 3.0k
June A. Peters United States 21 287 0.6× 586 1.2× 55 0.2× 202 0.6× 232 0.8× 66 2.2k
Brenda M. Birmann United States 25 397 0.8× 540 1.1× 70 0.2× 295 0.9× 223 0.7× 85 2.2k
David Oram United Kingdom 28 296 0.6× 436 0.9× 295 0.8× 343 1.0× 255 0.8× 64 3.3k
Philippe Vennin France 17 182 0.4× 231 0.5× 181 0.5× 132 0.4× 125 0.4× 56 1.1k
Charmaine Kim‐Sing Canada 34 1.1k 2.1× 596 1.2× 75 0.2× 635 1.9× 567 1.9× 61 3.7k
Mary B. Daly United States 18 963 1.9× 787 1.6× 125 0.4× 468 1.4× 744 2.4× 36 3.6k

Countries citing papers authored by Dawn Everington

Since Specialization
Citations

This map shows the geographic impact of Dawn Everington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawn Everington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawn Everington more than expected).

Fields of papers citing papers by Dawn Everington

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawn Everington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawn Everington. The network helps show where Dawn Everington may publish in the future.

Co-authorship network of co-authors of Dawn Everington

This figure shows the co-authorship network connecting the top 25 collaborators of Dawn Everington. A scholar is included among the top collaborators of Dawn Everington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawn Everington. Dawn Everington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Molesworth, A M, et al.. (2012). Risk factors for variant Creutzfeldt-Jakob disease in dental practice: a case-control study. BDJ. 213(11). E19–E19. 4 indexed citations
2.
Pennington, Catherine, J. Mackenzie, Mary Andrews, et al.. (2010). The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. Journal of Neurology Neurosurgery & Psychiatry. 81(11). 1243–1248. 95 indexed citations
3.
Everington, Dawn, et al.. (2007). Dental treatment and risk of variant CJD – a case control study. BDJ. 202(8). E19–E19. 14 indexed citations
4.
Ward, Helen, Dawn Everington, Simon Cousens, et al.. (2007). Risk factors for sporadic Creutzfeldt–Jakob disease. Annals of Neurology. 63(3). 347–354. 37 indexed citations
5.
Willis, Joanna, Colin Smith, James W. Ironside, et al.. (2005). The accuracy of meningioma grading: a 10‐year retrospective audit. Neuropathology and Applied Neurobiology. 31(2). 141–149. 151 indexed citations
6.
Ward, Helen, Dawn Everington, Simon Cousens, et al.. (2005). Risk factors for variant Creutzfeldt–Jakob disease: A case–control study. Annals of Neurology. 59(1). 111–120. 78 indexed citations
7.
Ward, Helen, et al.. (2004). Obstacles to conducting epidemiological research in the UK general population. BMJ. 329(7460). 277–279. 69 indexed citations
8.
Cousens, Simon, et al.. (2003). The geographical distribution of variant Creutzfeldt-Jakob disease cases in the UK: what can we learn from it?. Statistical Methods in Medical Research. 12(3). 235–246. 6 indexed citations
9.
McCormack, James E., Herbert Baybutt, Dawn Everington, et al.. (2002). PRNP contains both intronic and upstream regulatory regions that may influence susceptibility to Creutzfeldt–Jakob Disease. Gene. 288(1-2). 139–146. 38 indexed citations
10.
Cousens, Simon, Peter G. Smith, Helen Ward, et al.. (2001). Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994–2000. The Lancet. 357(9261). 1002–1007. 75 indexed citations
11.
Martín, C., RA Anderson, L. Cheng, et al.. (2000). Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Human Reproduction. 15(3). 637–645. 173 indexed citations
12.
Martín, C., Simon C. Riley, Dawn Everington, et al.. (2000). Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary–testicular axis in normal men*. Human Reproduction. 15(7). 1515–1524. 43 indexed citations
14.
Glasier, Anna, Raymond Anakwe, Dawn Everington, et al.. (2000). Would women trust their partners to use a male pill?. Human Reproduction. 15(3). 646–649. 140 indexed citations
15.
Anderson, Richard A., C. Martín, Dawn Everington, et al.. (1999). 7α-Methyl-19-Nortestosterone Maintains Sexual Behavior and Mood in Hypogonadal Men*. The Journal of Clinical Endocrinology & Metabolism. 84(10). 3556–3562. 77 indexed citations
16.
Everington, Dawn, et al.. (1996). Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. British Journal of Cancer. 74(2). 297–299. 118 indexed citations
17.
Forrest, A P M, Helen Stewart, Dawn Everington, et al.. (1996). Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. The Lancet. 348(9029). 708–713. 310 indexed citations
18.
Jack, W, Dawn Everington, A. Rodger, A P M Forrest, & HelenJ. Stewart. (1995). Adjuvant therapy with 5-fluorouracil for breast cancer of likely poor prognosis: 15-year results of a randomized trial. Clinical Oncology. 7(1). 7–11. 4 indexed citations
19.
Forrest, A P M, Dawn Everington, C. McDonald, et al.. (1995). The Edinburgh randomized trial of axillary sampling or clearance after mastectomy. British journal of surgery. 82(11). 1504–1508. 103 indexed citations
20.
Walker, R. A., et al.. (1990). Is apocrine differentiation in breast carcinoma of prognostic significance?. British Journal of Cancer. 62(1). 113–117. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026